Medexus Pharmaceuticals Inc
TSX:MDP
Intrinsic Value
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease... [ Read More ]
The intrinsic value of one
MDP
stock under the Base Case scenario is
8.19
CAD.
Compared to the current market price of 1.65 CAD,
Medexus Pharmaceuticals Inc
is
Undervalued by 80%.
Medexus Pharmaceuticals Inc's market capitalization is 40.4m CAD.
MDP stock price is 1.65 CAD.
MDP stock price (1.65 CAD) is 80% less than its Intrinsic Value (8.19 CAD).
MDP has upside potential of 101% compared to the average analyst price target.
Open Wall St Estimates
MDP's Revenue has been growing by 2% per year for the last 3 years.
MDP's short-term assets (74m USD) exceed its short-term liabilties (66m USD).
MDP's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
MDP's Revenue has grown by 16% over the past 12 months.
MDP's long-term assets (160m USD) exceed its long-term liabilties (131m USD).
MDP's D/E (Debt to Equity) is equal to 1.26.
MDP's ROE (Return on Equity) for the past 12 months is very high and is equal to 26%.
MDP has positive Operating Income for the last twelve months.
MDP's ROE (Return on Equity) has significantly increased in the last 3 years from -134% to 26%.
MDP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 0% to -79%, and is approaching profitability.
MDP has positive Net Income for the last twelve months.
MDP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -79%.
MDP has positive Gross Profit for the last twelve months.
MDP has positive Free Cash Flow for the last twelve months.
MDP has positive Net Debt. This means that the company has more debt (37m USD) than cash and short-term investments (8m USD).
MDP has negative three-year average ROIC (Return on Invested Capital): -14%. The company is not efficient at using invested capital to generate operating income.
MDP has negative three-year average ROE (Return on Equity): -43%. The company is not efficient at transforming stockholders' equity into net income.
MDP's Altman Z-Score is very low and is equal to 0.69.
MDP generates enough operating income (13m USD) to cover interest payments on its debt (5m USD).
Valuation Backtest
Medexus Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MDP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Medexus Pharmaceuticals Inc
Balance Sheet Decomposition
Medexus Pharmaceuticals Inc
| Current Assets | 74.1m |
| Cash & Short-Term Investments | 8.2m |
| Receivables | 22.2m |
| Other Current Assets | 43.6m |
| Non-Current Assets | 86.3m |
| PP&E | 843k |
| Intangibles | 76.8m |
| Other Non-Current Assets | 8.7m |
| Current Liabilities | 66.5m |
| Accounts Payable | 43.4m |
| Other Current Liabilities | 23.1m |
| Non-Current Liabilities | 64.3m |
| Long-Term Debt | 37.2m |
| Other Non-Current Liabilities | 27.1m |
Earnings Waterfall
Medexus Pharmaceuticals Inc
|
Revenue
|
115.7m
USD
|
|
Cost of Revenue
|
-54.5m
USD
|
|
Gross Profit
|
61.2m
USD
|
|
Operating Expenses
|
-48.4m
USD
|
|
Operating Income
|
12.8m
USD
|
|
Other Expenses
|
-6.9m
USD
|
|
Net Income
|
5.9m
USD
|
Free Cash Flow Analysis
Medexus Pharmaceuticals Inc
MDP Profitability Score
Profitability Due Diligence
Medexus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Medexus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
MDP Solvency Score
Solvency Due Diligence
Medexus Pharmaceuticals Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Medexus Pharmaceuticals Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDP Price Targets Summary
Medexus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MDP
is 3.32 CAD
with a low forecast of 2.02 CAD and a high forecast of 6.2 CAD.
Shareholder Return
MDP Price
Medexus Pharmaceuticals Inc
| Average Annual Return | -5.27% |
| Standard Deviation of Annual Returns | 55.57% |
| Max Drawdown | -91% |
| Market Capitalization | 40.4m CAD |
| Shares Outstanding | 24 458 213 |
| Percentage of Shares Shorted | 0.08% |
Company Profile
Medexus Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
Contact
IPO
Employees
Officers
The intrinsic value of one
MDP
stock under the Base Case scenario is
8.19
CAD.
Compared to the current market price of 1.65 CAD,
Medexus Pharmaceuticals Inc
is
Undervalued by 80%.
You don't have any saved screeners yet
